Abstract
Adenosine receptors belong to the family of G protein-coupled receptors. Four distinct subtypes are known, termed A1, A2A, A2B and A3. Adenosine is an important signaling molecule which is released under inflammatory conditions. It can show antiinflammatory as well as proinflammatory activities, and the contribution of the specific adenosine receptor subtypes in various cells, tissues and organs is complex. Agonists selective for adenosine A1 receptors show antinociceptive activity and are active in animal models of neuropathic and inflammatory pain. Adenosine A2A receptor agonists are potent antiinflammatory drugs. A2A-selective antagonists have shown antihyperalgesic activity in animal models of inflammatory pain. For A2B agonists as well as A2B antagonists antiinflammatory activity has been postulated. Selective A2B antagonists were shown to decrease (inflammatory) pain, and are promising candidates for the treatment of asthma. Adenosine A3 receptor agonists appear to be proinflammatory, while there is evidence for an antiinflammatory effect of A3 antagonists. There are some contradictory findings, and A 3 agonists are being developed for the treatment of inflammatory diseases such as arthritis. Indirect mechanisms increasing the extracellular concentration of adenosine using adenosine kinase inhibitors, adenosine deaminase inhibitors or adenosine uptake inhibitors, or increasing the potency of adenosine at the A1 receptor subtype by allosteric modulators lead to potent antinociceptive and antiinflammatory activity. The advantage of indirectly acting drugs may be their site- and event-specific action since they are only active where adenosine has been released. In the past decade considerable progress has been made towards the identification of novel lead structures and the development of potent and selective ligands for all four adenosine receptor subtypes. A large number of patents has recently been filed and the field is finally in the process of translating many years of basic science into therapeutic application. This review article will focus on compounds published or patented within the past three years.
Keywords: Xanthine antagonist, Pyridazinone derivatives, pyrazine derivatives, inflammation, MRE-0094, Asthma
Current Topics in Medicinal Chemistry
Title: Recent Progress in the Development of Adenosine Receptor Ligands as Antiinflammatory Drugs
Volume: 6 Issue: 13
Author(s): Rhalid Akkari, Joachim C. Burbiel, Jorg Hockemeyer and Christa E. Muller
Affiliation:
Keywords: Xanthine antagonist, Pyridazinone derivatives, pyrazine derivatives, inflammation, MRE-0094, Asthma
Abstract: Adenosine receptors belong to the family of G protein-coupled receptors. Four distinct subtypes are known, termed A1, A2A, A2B and A3. Adenosine is an important signaling molecule which is released under inflammatory conditions. It can show antiinflammatory as well as proinflammatory activities, and the contribution of the specific adenosine receptor subtypes in various cells, tissues and organs is complex. Agonists selective for adenosine A1 receptors show antinociceptive activity and are active in animal models of neuropathic and inflammatory pain. Adenosine A2A receptor agonists are potent antiinflammatory drugs. A2A-selective antagonists have shown antihyperalgesic activity in animal models of inflammatory pain. For A2B agonists as well as A2B antagonists antiinflammatory activity has been postulated. Selective A2B antagonists were shown to decrease (inflammatory) pain, and are promising candidates for the treatment of asthma. Adenosine A3 receptor agonists appear to be proinflammatory, while there is evidence for an antiinflammatory effect of A3 antagonists. There are some contradictory findings, and A 3 agonists are being developed for the treatment of inflammatory diseases such as arthritis. Indirect mechanisms increasing the extracellular concentration of adenosine using adenosine kinase inhibitors, adenosine deaminase inhibitors or adenosine uptake inhibitors, or increasing the potency of adenosine at the A1 receptor subtype by allosteric modulators lead to potent antinociceptive and antiinflammatory activity. The advantage of indirectly acting drugs may be their site- and event-specific action since they are only active where adenosine has been released. In the past decade considerable progress has been made towards the identification of novel lead structures and the development of potent and selective ligands for all four adenosine receptor subtypes. A large number of patents has recently been filed and the field is finally in the process of translating many years of basic science into therapeutic application. This review article will focus on compounds published or patented within the past three years.
Export Options
About this article
Cite this article as:
Akkari Rhalid, Burbiel C. Joachim, Hockemeyer Jorg and Muller E. Christa, Recent Progress in the Development of Adenosine Receptor Ligands as Antiinflammatory Drugs, Current Topics in Medicinal Chemistry 2006; 6 (13) . https://dx.doi.org/10.2174/15680266106061375
DOI https://dx.doi.org/10.2174/15680266106061375 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
AlphaFold in Medicinal Chemistry: Opportunities and Challenges
AlphaFold, a groundbreaking AI tool for protein structure prediction, is revolutionizing drug discovery. Its near-atomic accuracy unlocks new avenues for designing targeted drugs and performing efficient virtual screening. However, AlphaFold's static predictions lack the dynamic nature of proteins, crucial for understanding drug action. This is especially true for multi-domain proteins, ...read more
Artificial intelligence for Natural Products Discovery and Development
Our approach involves using computational methods to predict the potential therapeutic benefits of natural products by considering factors such as drug structure, targets, and interactions. We also employ multitarget analysis to understand the role of drug targets in disease pathways. We advocate for the use of artificial intelligence in predicting ...read more
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Integrin α4β7 Antagonists: Activities, Mechanisms of Action and Therapeutic Prospects
Current Immunology Reviews (Discontinued) Adverse Drug Reactions in the Oral Cavity
Current Pharmaceutical Design Antihistamines as Important Tools for Regulating Inflammation
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Activin-A: A New Piece in the Puzzle of Tolerance in Asthma
Clinical Anti-Inflammatory & Anti-Allergy Drugs (Discontinued) Himalayan Plants as a Source of Anti-Cancer Agents: A Review
The Natural Products Journal Tumor Markers in Patients with Benign and Malignant Pulmonary Diseases; Competitive Evaluation of ProGRP, NSE and Cyfra 21-1
Recent Patents on Biomarkers The Interplay between the Gut Immune System and Microbiota in Health and Disease: Nutraceutical Intervention for Restoring Intestinal Homeostasis
Current Pharmaceutical Design Exploration of the Potential Mechanisms of Compounds from <i>Rheum palmatum L.</i> against Chronic Obstructive Pulmonary Disease: A Network Pharmacology Study
Combinatorial Chemistry & High Throughput Screening Structure and Function in COPD
Current Respiratory Medicine Reviews Rhinosinusitis in the Pediatric Patient with Cystic Fibrosis
Current Pediatric Reviews Cold-induced Anaphylaxis: The Case of a 9-year-old Child and Review of the Literature
Endocrine, Metabolic & Immune Disorders - Drug Targets Past Efforts and Future Prospects for a Nasal Influenza Vaccine
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) Subject Index
Current Drug Targets - Inflammation & Allergy Adipose-Derived Stromal/Stem Cells (ASC) in Regenerative Medicine: Pharmaceutical Applications
Current Pharmaceutical Design Effector Cells and Downstream Mediators in Severe Cutaneous Adverse Reactions
Current Immunology Reviews (Discontinued) Apoptosis Induction by Thalidomide: Critical for Limb Teratogenicity but Therapeutic Potential in Idiopathic Pulmonary Fibrosis?
Current Molecular Pharmacology IgE-Mediated Disorders: Current Therapeutics and New Strategies Involving Synthetic Peptides
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Pharmacological Treatment of Obstructive Sleep Apnea
Current Pharmaceutical Design Delivery Systems of Opioid Analgesics for Pain Relief: A Review
Current Pharmaceutical Design New Insights into the Immune Response to Pneumococci
Current Respiratory Medicine Reviews